J. Machiels

发表

Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor

R. Figlin, I. Davis, Thomas E. Hutson, 2008 .

An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).

O. Baadsgaard, E. Ehrnrooth, P. Clement, 2010, Journal of Clinical Oncology.

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies

E. Van Cutsem, J. Canon, M. Opyrchal, 2019, BioDrugs.

EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients

R. Semrau, A. Debucquoy, C. Sempoux, 2011, Clinical Cancer Research.

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

M. Ahn, R. Mehra, R. Swaby, 2021 .

Cancer vaccines

E. Jaffee, R. Reilly, J. Machiels, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of pathological response to preoperative chemoradiotherapy with cetuximab in rectal cancer

O. Gevaert, A. Debucquoy, A. Daemen, 2008 .

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

R. Figlin, R. Epstein, I. Davis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

S. Oudard, J. Bono, A. Sartor, 2010 .

Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC).

A. Ravaud, J. Machiels, H. von der Maase, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

S. Oudard, J. D. de Bono, L. Shen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study.

S. Oudard, J. D. de Bono, L. Shen, 2011, Journal of Clinical Oncology.

A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

S. Oudard, J. D. de Bono, L. Shen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)

B. Filleul, F. Mazzeo, J. Kerger, 2007 .

Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors.

S. Rottey, J. Vermorken, K. Pelling, 2010 .

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

J. Machiels, T. Meyer, S. Topalian, 2017 .

Predictive Biomarkers and Personalized Medicine EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients

R. Semrau, A. Debucquoy, C. Sempoux, 2011 .

Prognostic factors for survival in the phase III TROPIC trial.

S. Oudard, I. Bodrogi, G. Gravis, 2012, Journal of Clinical Oncology.

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.

R. Figlin, R. Epstein, I. Davis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.